Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MBI 226: Phase III

In a Phase III trial in 1,452 patients, MBI 226 did not meet the primary

Read the full 151 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE